TBC1D3L: A Potential Drug Target and Biomarker (G101060376)

Target Name: TBC1D3L

NCBI ID: G101060376

TBC1D3L

Other Name(s): TBC1 domain family member 3L | TBC1D3L variant 2 | TBC3L_HUMAN | TBC1 domain family member 3L (isoform 2) | TBC1 domain family member 3L, transcript variant 2

TBC1D3L: A Potential Drug Target and Biomarker

Tumor suppressor genes (TSGs) are important regulators of cancer growth and progression. They encode proteins that play a critical role in preventing the formation of tumors, and mutations in these genes have been implicated in the development of many types of cancer. One of the most promising TSGs under investigation is TBC1D3L, a gene that has been identified as a potential drug target and biomarker for cancer.

The TBC1D3L gene is located on chromosome 16 and encodes a protein known as TBC1D3L. This protein is involved in a variety of cellular processes, including cell signaling, DNA replication, and apoptosis (programmed cell death). TBC1D3L has been shown to play a key role in the regulation of cell growth and differentiation, and it is thought to be involved in the development of many types of cancer.

One of the most promising aspects of TBC1D3L is its potential as a drug target. The use of drugs that target specific proteins has been shown to be an effective way to treat many types of cancer. By inhibiting the activity of TBC1D3L, doctors may be able to reduce the growth of cancer cells and potentially slow down or even stop the development of cancer. This has the potential to be a highly effective form of cancer treatment.

In addition to its potential as a drug target, TBC1D3L is also being investigated as a biomarker for cancer. This means that researchers are trying to use it as a diagnostic tool to identify people who are at risk of developing cancer. By analyzing the levels of TBC1D3L in a person's body, doctors may be able to determine whether they have an increased risk of developing cancer. This could be a valuable tool for cancer screening and early detection.

The search for new treatments and biomarkers for cancer is an ongoing process, and the development of TBC1D3L as a drug target and biomarker is just one of the many areas of research being explored. As more and more information is learned about this protein, its potential as a drug and biomarker for cancer may continue to grow.

Overall, TBC1D3L is a promising protein for the development of cancer treatments. Its potential as a drug target and biomarker make it an important area of research to explore further. As more research is done on this protein, its potential in the fight against cancer may become even greater.

Protein Name: TBC1 Domain Family Member 3L

Functions: Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11 (By similarity)

The "TBC1D3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBC1D3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets